Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement-Reference-Cited by-同舟云学术

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

Published:2017-03-26 Issue:3 Volume:23 Page:e170-e179
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Iorio A.¹²^ORCID,Iserman E.¹,Blanchette V.³,Dolan G.⁴,Escuriola Ettingshausen C.⁵,Hermans C.⁶,Negrier C.⁷,Oldenburg J.⁸,Reininger A.⁹,Rodriguez-Merchan C.¹⁰,Spannagl M.¹¹,Valentino L. A.¹²,Young G.¹³,Steinitz-Trost K. N.⁹,Gringeri A.⁹

Affiliation:

1. Department of Health Research Methods; Evidence; and Impact; McMaster University; Hamilton Ontario Canada

2. Department of Medicine; McMaster University; Hamilton Ontario Canada

3. Department of Pediatrics; Division of Hematology/Oncology; Hospital for Sick Children; University of Toronto; Toronto Canada

4. Guy's and St Thomas’ Hospital; London UK

5. Haemophilia Centre Rhine Main - HZRM; Moerfelden-Walldorf Germany

6. Haemostasis and Thrombosis Unit; Division of Haematology; Cliniques universitaires Saint-Luc; Brussels Belgium

7. Division of Haematology; Louis Pradel Cardiology hospital; University Claude Bernard Lyon1; Lyon France

8. University Clinic Bonn; Bonn Germany

9. Global Medical Affairs Hematology; Baxalta Innovations GmbH; Vienna Austria

10. Department of Orthopaedic Surgery; La Paz University Hospital; Madrid Spain

11. Department of Transfusion Medicine and Hemostasis; University Hospital Munich; Munich Germany

12. Rush University and Baxalta, US, Inc.; Deerfield IL USA

13. Children's Hospital Los Angeles; University of Southern California Keck School of Medicine; Los Angeles CA USA

Funder

McMaster University

Baxalta

Shire

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13215/fullpdf

Reference21 articles.

1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

2. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B;Iorio;Cochrane Database Syst Rev,2011

3. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study);Gringeri;J Thromb Haemost,2011

4. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management;Valentino;J Thromb Haemost,2012

5. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART);Manco-Johnson;J Thromb Haemost,2013

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study;International Journal of Hematology;2023-12-15

2. Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis;Journal of Thrombosis and Haemostasis;2023-12

3. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review;Haemophilia;2023-09-27

4. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

5. Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis;CPT: Pharmacometrics & Systems Pharmacology;2023-03-25